PARP Inhibitors for BRCA-Linked Prostate Cancer Explained
PARP inhibitors work only against prostate cancers with BRCA or HRR mutations—a December 2025 FDA approval added a BRCA2 hormone-sensitive option.
fda approved prostate cancer drugs
When Chemotherapy for Prostate Cancer Is Needed
Hearing 'chemo' for prostate cancer is frightening, but it's used only when the cancer has spread—often with hormone therapy. See when it helps and how.